JP2002080351A - Immunopotentiator - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a new immunopotentiator capable of preventing infectious diseases without using an antibiotic or a vaccine by enhancing the immunity of mammals, birds, fishes and the like, and having strong immunoenhancement effect. SOLUTION: The immunopotentiator contains a matter comprising astaxanthin-containing yeast or a treated matter of the yeast, which contains cell walls or their constituting components, and astaxanthin, as an active ingredient.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to an immunopotentiator, a feed additive comprising the same, and a feed containing the feed additive.

[0002]

2. Description of the Related Art Conventionally, in animal husbandry, antibiotics and antibacterial agents have been added to feed in order to increase the production efficiency of livestock. These drugs are used not for protection against pathogen infection but for enhancing body weight gain and improving feed efficiency. Disadvantages of these drugs are that, when used continuously for a long period of time, bacteria resistant to the administered drugs selectively increase, change into a specific flora in vivo, and the emergence of resistant bacteria. Can be raised. Therefore, the effect of the drug is attenuated by continuous use, and the economical loss is thereby increased.

[0003] Also, the flora selected by the drug results in the appearance of a new disease. For example, long-term administration of antibiotics that are highly effective against Gram-negative bacteria to livestock for the purpose of purifying the contamination of outdoor farms may cause the intestinal flora to selectively transform into putrefactive bacteria, causing chronic diarrhea. It is known to develop. In other words, among the pathogenic microorganisms of livestock, especially for Gram-negative bacteria such as Escherichia coli, it is known that the distribution and microflora in the intestinal tract change when a high protein feed is fed or when feeds with different compositions are switched. Have been. For example, it is known that when a high protein feed is given to a suckling piglet, Escherichia coli appears in the upper small intestine, which is not usually observed. In addition, when a piglet is fed a feed with different raw materials and components in a short period of time, special Escherichia coli appears and diarrhea frequently occurs.

[0004] As a countermeasure against this, for example, when a therapeutic amount of an antibiotic such as colistin, which is highly effective against gram-negative bacteria, is administered to a calf or a piglet during a long term, the number of E. coli in feces becomes extremely high. Although it is less, spoilage bacteria such as proteus, which are not usually found, occupy the mainstream of the flora, and depending on those bacteria, they may show long-term diarrhea symptoms.

On the other hand, in the field, there are various pathogenic bacteria, viruses and protozoa other than Escherichia coli, which exhibits pathogenicity, and their prevention and treatment methods are complicated and countermeasures are difficult. In addition, productivity was extremely reduced due to the combined infection of virus and bacteria, but some farms were observed, and cases where improvement was not achieved by hygiene measures centered on drugs were recognized.

[0006] As a preventive measure against infection by various pathogenic microorganisms in the field, vaccines are used, but vaccines against a large number of pathogenic bacteria must be developed, which requires a great deal of labor and cost. In addition, even if a vaccine against a specific pathogen is developed, it may be ineffective or extremely ineffective due to differences in the strain of the specific pathogen, and in particular, it is impossible to completely prevent the onset of bacterial infectious diseases. Have difficulty.

[0007] In recent years, in the case of a disease that dies in an acute course due to infection with a pathogenic microorganism, it may be difficult to solve the disease only by treatment with drug administration or proper breeding management. Therefore, there is a demand for the development of a preventive method and a means using as little drug as possible.

[0008] Techniques for enhancing the productivity by raising the immunity of domestic animals are known in Japanese Patent Publication No. 6-55107, JP-A-7-126178, and others. In addition, for humans,
538 and Patent No. 2796635. These inventions use cells obtained as by-products of the fermentation industry in the production of bifidobacteria, lactic acid bacteria, and other amino acids, and the immunological main component of these cells is peptidoglycan present in the cell wall. . Also, conventionally known brewing yeasts and the like are known that β-glucan, which is a cell wall component, exhibits an immunological effect.

[0009]

Although these immunopotentiators are considered to be effective in preventing infectious diseases, it goes without saying that it would be desirable to provide an immunopotentiator having a better immunopotentiating effect. .

[0010] It is an object of the present invention to enhance the immunity of mammals, birds, fish, etc., thereby preventing infectious diseases without using antibiotics and vaccines, and having a strong immunopotentiating effect. It is to provide a novel immunopotentiator having the following.

[0011]

Means for Solving the Problems As a result of intensive studies, the present inventors have found that yeast containing astaxanthin exhibits an excellent immunopotentiating effect and completed the present invention.

[0012] That is, the present invention provides an immunopotentiator comprising, as an active ingredient, a yeast containing astaxanthin or a processed product of the yeast, which contains a cell wall or a component thereof and astaxanthin. Also, the present invention
A feed additive comprising the immunopotentiator is provided. further,
The present invention provides a feed containing the feed additive in an amount of 0.001 to 0.02% by weight of yeast.

[0013]

BEST MODE FOR CARRYING OUT THE INVENTION Astaxanthin is a carotenoid which usually exhibits red to yellow color, and is widely distributed in the body surface of algae, tropical fish, red sea bream, etc., and in marine organisms such as crabs and shrimp shells. It has been reported that the term oxygen scavenging action is several hundred times as active as α-tocopherol.
Antioxidant activity against lipid peroxidation caused by free radicals has also been demonstrated.

When such functions of antioxidant components are examined immunologically, immunocompetent cells such as macrophages produce superoxide and hydrogen peroxide in the cells and oxidize bacteria that have eaten the food. On the other hand, antioxidant components such as astaxanthin have been considered as immunosuppressive components because they neutralize them.

According to the present invention, the effect of coexistence of β-glucan, an immunologically active component, and astaxanthin, an antioxidant component, is not immunosuppressive, but is resistant to artificial infection of Escherichia coli in mice. The present invention was first clarified, and a new use as an immunopotentiator having excellent storage stability was found.

As described above, the immunopotentiator of the present invention contains, as an active ingredient, a yeast containing astaxanthin or a processed product of the yeast, which contains a cell wall and astaxanthin. As yeast containing astaxanthin, yeast belonging to the genus Phaffia is preferable, and in particular,
Phaffia rhodozyma is preferred. Phaffia rhodozyma itself is a well-known yeast,
They have been deposited with IFO and ATCC under accession numbers such as IFO 10129, IFO 10130, ATCC 24201 and ATCC 24261, and can be freely distributed.

Phaffia rhodozyma (Phaffia rhodozyma) is a red yeast discovered by MILLER et al in 1976, and is currently used as a feed for coloring fish and crustaceans and for coloring yolk of laying hens. Used. The red pigment is astaxanthin and is contained in yeast cells. The astaxanthin content in yeast is 3 to 9 mg / g, and it is known that astaxanthin has antioxidant properties such as singlet oxygen scavenging ability.

The yeast contained in the immunopotentiator of the present invention may be live or dead. Also,
The bacterium may be dried or freeze-dried. Furthermore, the immunopotentiator may be a processed product of the yeast, which contains a cell wall and astaxanthin as an active ingredient. Preferred examples of such a processed yeast include mechanical treatment (whole meal treatment, ultrasonic treatment,
It may be produced by any method such as French press, homogenizer treatment, etc., enzyme treatment (glucanase, protease, etc.) and chemical treatment (eg, treatment with an alkaline reagent such as caustic soda or caustic potash). The processed yeast may be further dried or freeze-dried. Anyway, any yeast cell treated product containing astaxanthin contained in yeast and the cell wall of yeast or a component thereof (particularly β-glucan) can be used as an active ingredient of the immunopotentiator of the present invention.

The immunopotentiator of the present invention preferably further contains an antioxidant which suppresses the oxidation of astaxanthin, in addition to the above-mentioned active ingredient for enhancing immunity. As the antioxidant, any substance can be used as long as it can suppress the oxidation of astaxanthin. Preferred examples thereof include buckwheat, acacia, coffee, tea, hawthorn, turmeric or garlic, or Can be included. In addition, any of these plants can be used as long as they contain an antioxidant component capable of suppressing the oxidation of astaxanthin. Preferably, buckwheat is a grain, sensilla is a leaf or a branch, coffee is a bean, tea is a leaf, hawthorn is a fruit (especially flesh), turmeric is a tuber or rhizome, and garlic is a bulb. Also, extracts of these plants (preferably hot water or ethanol extracts) can be preferably used as long as they contain an antioxidant component capable of suppressing the oxidation of astaxanthin. These antioxidants can be used alone or in combination of two or more.

Buckwheat (F. esculentum, F. tataricum)
It is classified into the genus Buckwheat (Fagopyrum) of the Polygonaceae family, and is usually buckwheat (F. esculentum) and buckwheat (F.ta)
taricum), and more than a dozen species have been confirmed including wild species. Common buckwheat is buckwheat that is usually consumed and is cultivated in Japan, China, Russia, Canada, the United States, Poland, and the like. Tartary buckwheat, also known as bitter buckwheat, is one of the traditional crops of the Himalayas such as Nepal. The grain contains a large amount of bitter components. Rutin is known as an antioxidant component of buckwheat, and these extracted components may be used.

Asenyaku (Asenyaku; Uncaria gambir)
Is a plant of the Rubiaceae family, and extracts from leaves and shoots are used as antidiarrheal and oral fresheners. It is mainly grown in Southeast Asia (Indonesia, Malaysia, etc.). The antioxidant component of Asenyak is catechins, querceti
n), gambiriin is known, and these extracts may be used.

Coffee is a major species of Arabica, robusta and liberica, and is grown in Central and South America, Africa and parts of Asia. The main ingredients in coffee beans are caffeine and chlorogenic acid.
ids) are known. Chlorogenic acid is decomposed into quinic acid and caffeic acid during roasting and changes into components such as brown pigment. As the antioxidant component of coffee, chlorogenic acid and caffeic acid, which is a decomposition product, are known, and these extracted components may be used.

Tea (Camellia sinensis) contains catechin, caffeine, vitamin C, vitamin E, etc.
Many physiological actions are known in addition to antibacterial action, antioxidant action, active oxygen scavenging action, antiallergic action. Raw materials used in the present invention may be any of ordinary tea, powdered tea out of the standard generated in the manufacturing process, extraction residue and tea infusion liquid solids generated in the manufacturing process, and may be thoroughly dried and pulverized. It is preferable to use them. As the antioxidant component of tea, catechins and vitamins E and C are known, and these extracted components may be used.

Hawthorn (Yamako) is a shrub of the family Rosaceae native to China. It is called Crataegus cuneata or Crataegus pinnatifida and contains a lot of citric acid, minerals, carotene, etc. It is used for nutritional supplementation, daily health maintenance, improvement of indigestion and chronic diarrhea, pacification of stomach. In addition, effects such as normalization of blood cholesterol and suppression of increase in lipid peroxide are known. As the Yamadoko used in the present invention, a dried pulp, an extracted extract and a dried product thereof are preferable. As antioxidant components of hawthorn, catechins, quercetin, chlorogenic acid and vitamin C are known, and these extracted components may be used.

Turmeric (Curcuma rhizoma) belongs to the ginger family and is generally known by the names spring turmeric and autumn turmeric. Spring turmeric is mainly used for medicinal purposes, and autumn turmeric is used as a turmeric as a coloring material such as curry powder and turkey. Origin is from tropical Asia, India,
It is preferably cultivated widely in southern China, Okinawa, and the like, and the tuber or rhizome portion of the plant is preferably used after drying.
The pharmacological effect of turmeric is mainly known for its bile effect, and is used for the prevention and treatment of hepatitis, cholangitis and cholelithiasis.

The turmeric used in the present invention may be either spring turmeric or autumn turmeric, or may be a mixture of spring turmeric and autumn turmeric according to the purpose of use. For feed,
Dry and powdered residuals such as rhizome skin and tuberous whiskers can also be used. Curcumin is known as an antioxidant component of turmeric, and these extracted components may be used.

Garlic (Allium scorodoprasum) belongs to the lily family, and it is usually preferable to dry its bulbs before use. Garlic contains glycoside glycosides,
Upon hydrolysis, an essential oil containing sulfur is obtained. Essential oils contain diallyl sulfide, an aroma component. Also,
Salicin in garlic has been shown to have physiological activities such as improving the absorption of vitamin B1 in the intestinal tract. A component of garlic (s-allyl cysteine and its metabolite) has been reported to have an effect of suppressing the oxidation of low-density cholesterol (LDL) in blood. Therefore, an extract of garlic having a known antioxidant property may be used.

The immunopotentiator of the present invention includes humans; mammals such as livestock and pets such as cows, pigs, horses, sheep, goats, dogs and cats; poultry such as chickens and turkeys;
It can be applied to seafood such as Thailand, prawns and clams.

The immunopotentiator of the present invention can be administered orally; parenteral administration such as intravenous injection, subcutaneous injection, intramuscular injection, or intraperitoneal injection, but oral administration is simple and preferred. The dosage is not particularly limited. In the case of oral administration, usually, the amount of yeast per kg of body weight per day (when using a processed yeast, the amount of yeast used as a raw material) is preferably about 0.1 mg to 20 mg, In the case of parenteral administration, this amount is preferably about 1/2 to 1/10.

The immunopotentiator of the present invention may be composed of only yeast or a processed yeast product, or may contain various excipients and additives that are suitable for the administration route and are commonly used in the pharmaceutical field. Is also good.

When the above-mentioned antioxidant substance is used, its amount is not particularly limited as long as it can significantly suppress the oxidation of astaxanthin. About 99.5% by weight.

The immunopotentiator of the present invention can be used not only as a medicine, but also as an additive for human food and feed for poultry, livestock or fish and shellfish. When used as an additive for feed, the amount of addition is preferably 0.001 to 0.02% by weight, more preferably 0.005 to 0.01% by weight, based on the total amount of yeast or processed yeast based on the whole feed.

[0033]

DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below more specifically based on embodiments. However, the present invention is not limited to the following examples.

Reference Example 1 (1) Storage stability of astaxanthin contained in yeast Yeast (Phafia rhodozyma (IFO 10129 strain).
In Reference Examples and Examples, when simply referred to as "yeast" or "Phafia yeast" means Phaffia rhodozyma), for the purpose of confirming the storage stability of astaxanthin contained therein, crushing treatment by mechanical treatment (ball meal treatment) The sample thus obtained was stored at room temperature and under severe conditions of 40 ° C. and 70% RH, and the stability of the amount of trans-astaxanthin was observed. The results are shown in Table 1 below.

[0035]

[Table 1] Table 1 (Unit: mg / g) * Severe conditions: 40 ℃, 70% RH

Reference Example 2 (2) Storage stability of astaxanthin in feed In order to confirm the storage stability of astaxanthin contained in yeast in feed, mechanical treatment (ball meal treatment) and chemical treatment (alkali treatment) )), A sample prepared by the method was added to feed at 0.08%, stored at room temperature, and the amount of trans-astaxanthin after storage for 1 and 2 months was measured. The results are shown in Table 2 below. In the alkali treatment, 10 N NaOH was used as an alkali, and 10 ml was used for 5 g of the dried yeast suspended in 1000 ml of a buffer solution, followed by treatment at 25 ° C. for 60 minutes. Neutralized with hydrochloric acid, the cells were separated by centrifugation, and dried with a spray drier to obtain alkali-treated Phaffia yeast. In the following examples, the treated yeast obtained by ball-milling the yeast may be referred to as “Phafia yeast 1”, and the treated yeast subjected to the alkali treatment as described above may be referred to as “Phafia yeast 2”.

[0037]

[Table 2] Table 2 (Unit: μg / g) * Amount of trans-astaxanthin; analysis value

Example 1 Protection Test for Escherichia coli Infection with Mice A sample of 500 μg / mouse of Phaffia yeast 1 was
Mice (females) were intraperitoneally administered 4 days and 1 day before inoculation of E. coli, and 1 MLD (mean lethal dose) of pathogenic E. coli was inoculated intraperitoneally into the mice, and the subsequent survival rate was observed. The results are shown in Table 3 below.

[0039]

[Table 3] Table 3 (Number of survivors) * At the time of inoculation; at the time of intraperitoneal inoculation of E. coli

The test mice showed a remarkable effect on the challenge of E. coli by the administration of the sample. These results suggested that immunocompetent cells such as neutrophils and macrophages were activated by the administration of the yeast, and the resulting E. coli elimination effect was suggested.

Example 2 Protection Test for Escherichia coli Infection by Chick A sample of Phaffia yeast 1 was suspended in physiological saline, and a 2-week-old broiler (chunky species, female) was orally administered at a dose of 500 μg / wing equivalent. After hours, septic pathogenic E. coli (O-2
1 × 10 ⁷ (cfu) per bird was intravenously inoculated. The survival rate of the test chicks 7 days after inoculation was improved by the administration of the sample (Table 4).

[0042]

Table 4 Chick survival rate (%)

Example 3 Immunological Stability Phaffia yeast 1 was stored under the condition of 5 ° C. for 6 months, and an Escherichia coli infection test was performed using a mouse. That is, 500 μg of each sample at the start of storage and 6 months after storage
/ Mouse was intraperitoneally administered 4 days and 1 day before inoculation of E. coli, and 1 MLD of E. coli was inoculated intraperitoneally of the mouse, and the subsequent survival rate was observed. As shown in Table 5, the protective effect of the sample after 6 months storage was hardly reduced and maintained. From these results, it was confirmed that the activating effect of the sample on immunocompetent cells such as neutrophils and macrophages was not inactivated under storage conditions of 5 ° C. for 6 months, and the stability was excellent.

[0044]

[Table 5] Table 5 Number of survivors (number of survivors / number of test samples)

Example 4 Acute Toxicity Test in Mice In order to determine the toxicity of a machine-treated yeast (Phafia yeast 1) sample, an acute toxicity test by oral administration to mice (limit test; according to OECD & EPA guidelines) was performed to determine the mortality. Was observed. That is, a sample was adjusted to 10 male (5 week-old) ICR mice weighing 29.25 g at an average body weight of 5,000 mg / kg. Gavage was performed using a gastric probe, and the number of deaths and clinical findings after administration were observed for 7 days.

As a result, at the dose of 5,000 mg / kg body weight, all the animals survived, and no death or clinical abnormality was observed, and the toxicity was extremely low.

Example 5 Safety Test on Chicken In order to confirm the safety of Phaffia yeast 2, a 37-week-old laying hen (Decarb TX35; female) was administered with the yeast at a usual dose (0.001 to 0.01). A test feed supplemented with 0.05 to 0.1%, which was a 10-fold amount, was prepared and fed for 4 weeks.

As shown in Table 6, there was no difference in body weight gain, feed intake and egg production rate in each of the added groups as compared with the control, and no clinical abnormality was observed throughout the test period.

[0049]

[Table 6] Table 6 1) Weight gain: g / 4 weeks, feed intake: g / day / wing, egg production:%

Example 6 Preparation of Sample Containing Antioxidant (1) Additive containing Phaffia yeast and hawthorn (additive A) 5 g of Phaffia yeast 1 and 99.5 g of hawthorn extract powder were mixed, and 100 g Was made as an additive. The content of Phaffia yeast in feed when 0.1% of this additive is added to feed is
It becomes 0.005%.

(2) Additive Containing Phaffia Yeast, Asenyaku and Garlic (Additive B) 10 g of Phaffia yeast and 45 g each of senilla and garlic extract powder were mixed to prepare 100 g of additive. When 0.1% of this additive is added to the feed, the content of Phaffia yeast in the feed is 0.01%.

(3) Phaffia yeast, buckwheat, Asenyak,
Additive containing tea, hawthorn, turmeric and garlic (additive C) 2 g of Phaffia yeast and 14 g each of bitter buckwheat powder, acacia extract powder, tea powder, hawthorn squeeze powder, coffee grounds powder, turmeric powder and garlic The extracted powder was mixed, and 100 g of additive was made as a trial. Add this additive to feed
% Of Phaffia yeast in feed when added
2%.

Example 7 Storage Stability of Trial Additive in Feed In order to confirm the storage stability of the trial additive containing Phaffia yeast in the feed, 0.08% by weight of each sample was added to the feed and the temperature was adjusted to room temperature. After storage and storage for 1 and 2 months, the stability was measured using the amount of trans-astaxanthin as a guide. The results are shown in Table 7.

The storage stability of Additives A to C containing an antioxidant component was superior to that of adding yeast alone.

[0055]

Table 7 Table 7 (Unit: μg / g) * 7 kinds of raw materials and components; described in Example 6, (3)

Example 8 Protection Test for Escherichia coli Infection by Mice In order to determine the effect of Phaffia yeast as a feed additive, it was derived from Bifidobacterium which had been conventionally added to domestic animals (chicken, pigs, cows, fish) and had a known effect. The yeast was tested for immunological equivalence using peptidoglycan (PG) as a control. PG was prepared by the method described in Japanese Patent No. 1968047.

That is, 500 μg / sample of Phaffia yeast 1
Mice were intraperitoneally administered to ICR mice (females) 4 days and 1 day before inoculation of E. coli, and 1 MLD of E. coli was inoculated intraperitoneally to evaluate the resistance to artificial infection of E. coli.
It was compared with the case of administration.

As shown in Table 8, the results were equivalent to the results obtained with PG administration. From these results, it is expected that Phaffia yeast has the same effect as PG even when used in livestock feed.

[0059]

Table 8 (Number of survivors) * At the time of inoculation; at the time of intraperitoneal inoculation of Escherichia coli * At the beginning of the mouse; 10 each

[0060]

As described above, according to the present invention, there is provided an immunopotentiator capable of enhancing immunity of mammals including humans, poultry, and the like, and preventing the onset of disease. There is also provided a feed additive comprising the immunopotentiator.

The raw materials used in the present invention are Phaffia yeast and its crushed products, plant materials derived from natural products, and plant materials of which safety is recognized, and their dried and crushed or extracted dried products or components. The use of these feeds and additives provides safe livestock products because there is almost no problem of the appearance and side effects of the drug and there is no concern about the effect of the drug residue on the human body. Furthermore, it can be safely used as an additive necessary for maintaining the health of mammals other than farms and livestock in which the productivity is not improved by the drug.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI Theme coat ゛ (Reference) A23K 1/18 102 A23K 1/18 102B 4C087 A61K 31/121 A61K 31/121 4C088 31/192 31/192 4C206 31/353 31/353 31/355 31/355 31/375 31/375 31/475 31/475 35/72 35/72 35/78 35/78 EJ CH V 45/06 45/06 A61P 37 / 04 A61P 37/04 43/00 171 43/00 171 // C12N 1/16 C12N 1/16 J (C12N 1/16 (C12N 1/16 J C12R 1: 645) C12R 1: 645) (72) Inventor Takanori Ogine 1708-2, Sakuya, Oaza, Tsukuba, Ibaraki Pref.National Agricultural Cooperative Association Fed and Livestock Central Research Laboratory Federation Livestock Central Research Institute In-house F-term (reference) 2B005 DA01 DA05 GA01 GA06 GA07 MB02 MB07 2B150 AA01 AA05 AA07 AA08 AA20 AB10 AC24 DA08 DB01 DD11 DD17 DD31 DD57 DE13 DE15 4B065 AA72X AC14 BD43 CA43 4C084 AA19 MA52 NA05 Z14 ZC09A ZB09A ZB09A ZB09A BA18 CB19 MA01 MA02 MA04 NA05 NA14 ZB09 ZB35 ZC61 ZC75 4C087 AA01 AA02 BC11 CA37 MA01 MA02 MA52 NA05 NA14 ZB35 ZC61 ZC75 4C088 AB14 AB43 AB45 AB51 AB59 AB81 AB88 BA08 BA33 MA02 MA52 NA05 NA14 ZB09 ZB35 A02 ZB09 ZB35 ZC09 AB01 MA04 MA72 NA05 NA14 ZB09 ZB35 ZC61 ZC75

Claims (10)

[Claims] 1. An immunopotentiator comprising, as an active ingredient, a yeast containing astaxanthin or a processed product of the yeast, which contains a cell wall or a component thereof and astaxanthin. 2. The immunopotentiator according to claim 1, wherein the yeast is a yeast belonging to the genus Phaffia. 3. The immunopotentiator according to claim 2, wherein the yeast is Phaffia rhodozyma. 4. The immunopotentiator according to claim 1, further comprising an antioxidant which suppresses astaxanthin oxidation. 5. The method according to claim 5, wherein the antioxidant substance is buckwheat,
The immunopotentiator according to claim 4, which is coffee, tea, hawthorn, turmeric or garlic, or an antioxidant component contained therein. 6. The immunopotentiator according to claim 5, wherein the antioxidant component is a catechin, rutin, quercetin, gambirin, chlorogenic acid, caffeic acid, vitamin E, vitamin C or curcumin. 7. The method according to claim 1, wherein the antioxidant substance is buckwheat,
The immunopotentiator according to claim 5, which is an extract of coffee, tea, hawthorn, turmeric or garlic. 8. A feed additive comprising the immunopotentiator according to any one of claims 1 to 7. 9. The feed additive according to claim 8, which is a feed additive for poultry, livestock or fish and shellfish. 10. The feed additive according to claim 8 or 9,
Feed containing 0.001 to 0.02% by weight of yeast.